Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2020-03-12 AGM Information
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for InnoTherapy. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2020-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted by InnoTherapy to explain why their Annual General Meeting (AGM) is being held on a 'concentrated date' (a date when many other companies are also holding their AGMs). It is a specific regulatory disclosure required by the KOSDAQ exchange regarding meeting logistics and scheduling, rather than the AGM materials themselves or a proxy statement. Since it is a regulatory notification regarding corporate governance scheduling, it falls under the RNS category.
2020-03-12 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for InnoTherapy. It contains the meeting agenda, details on voting procedures, and management information including board activities and financial statements (balance sheets, income statements) for the fiscal year. This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the Proxy Solicitation & Information Statement category.
2020-03-12 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific employees and executives, including the number of shares, exercise price, and vesting periods. This type of disclosure regarding the issuance of new equity-based compensation instruments falls under the category of share issuance or capital changes, which is best classified as 'SHA' (Share Issue/Capital Change).
2020-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) disclosing a significant change (over 30%) in revenue or profit structure, which is a standard mandatory disclosure requirement in the Korean stock market (KRX). It provides a summary of financial performance (revenue, operating profit, net income) compared to the previous year. Since this is an initial announcement of financial results (key highlights) rather than a full annual report or a transcript, it falls under the Earnings Release category. FY 2019
2020-02-13 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 1% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service in South Korea. It details the finalization of a tangible asset acquisition (real estate) previously announced in a major report. Since this document reports the completion of a specific corporate transaction (asset acquisition) rather than a merger or takeover bid, and it does not fit into the specific M&A category (which usually implies corporate entity mergers), it is classified as a Regulatory Filing (RNS) as it is a formal disclosure of a completed corporate event.
2020-01-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.